Asio Capital LLC Reduces Stake in IQVIA Holdings Inc.

Asio Capital LLC has significantly reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 59.2% during the fourth quarter of the year. This information was disclosed in the company's latest Form 13F filing with the Securities and Exchange Commission. After selling 6,233 shares during this time, Asio Capital LLC now owns 4,304 shares of the medical research company, which had a total value of about $846,000 at the end of the reporting period.

In addition to Asio Capital's adjustments, other institutional investors have also made changes to their positions in IQVIA. Capital Performance Advisors LLP entered into a new investment in IQVIA during the third quarter, approximately valued at $27,000. Similarly, Park Place Capital Corp acquired new shares in IQVIA, worth about $28,000. Avior Wealth Management LLC boosted its stake in IQVIA by 117.6% during the same quarter, bringing its total to 161 shares valued at $38,000 after purchasing an additional 87 shares. Assetmark Inc. raised its holdings significantly by 612.5% during the third quarter, now owning 228 shares worth $54,000 after acquiring an additional 196 shares. Lastly, UMB Bank n.a. increased its position in IQVIA by 74.4%, owning 232 shares valued at $55,000 after adding 99 shares during the period. In total, institutional investors hold approximately 89.62% of the shares in IQVIA.

IQVIA Stock Performance Overview

The shares of IQVIA Holdings Inc. opened on Friday at $204.54. The company exhibits a 50-day simple moving average of $199.71 and a 200-day simple moving average of $221.06. Over the past year, IQVIA's stock has reached a low of $187.62 and a high of $261.73. The current market capitalization of the company stands at $37.12 billion, with a price-to-earnings ratio of 26.84, a P/E/G ratio of 2.14, and a beta of 1.48. Furthermore, the company's debt-to-equity ratio is 1.76, along with a quick ratio and current ratio both at 0.81.

Analyst Ratings and Changes

Multiple brokerages have provided their insights regarding IQVIA's stock. On November 19th, Leerink Partners reiterated an "outperform" rating, adjusting the price target to $248.00, decreased from a previous $260.00. StockNews.com shifted its rating from "buy" to "hold" on November 28th. Additionally, Deutsche Bank reduced its price target from $270.00 to $265.00, maintaining a "buy" stance. The Goldman Sachs Group also lowered their target from $280.00 to $250.00 while holding a "buy" rating. Meanwhile, Barclays cut its price objective from $260.00 to $255.00, affirming an "overweight" rating for the stock. Currently, the stock has received ratings categorized as four holding, seventeen buy, and one strong buy according to ratings from MarketBeat, indicating an average rating of "Moderate Buy" with an average price target of $255.71.

About IQVIA Holdings Inc.

IQVIA Holdings Inc. is a prominent provider of advanced analytics, technology solutions, and clinical research services to the life sciences sector across the Americas, Europe, Africa, and the Asia-Pacific region. The company operates through three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Investment, Analysis, Markets